Kymera Therapeutics, Inc. (KYMR)

Market Cap	1.92B
Revenue (ttm)	47.07M
Net Income (ttm)	-223.86M
Shares Out	64.94M
EPS (ttm)	-2.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	357,092
Open	30.22
Previous Close	30.20
Day's Range	29.34 - 30.42
52-Week Range	29.07 - 53.27
Beta	2.23
Analysts	Buy
Price Target	56.69 (+91.39%)
Earnings Date	May 1, 2025

About KYMR

Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 21, 2020
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: KYMR
• Website: https://www.kymeratx.com

Financial Performance

In 2024, Kymera Therapeutics's revenue was $47.07 million, a decrease of -40.11% compared to the previous year's $78.59 million. Losses were -$223.86 million, 52.3% more than in 2023.

Analyst Forecast

According to 13 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56.69, which is an increase of 91.39% from the latest price.

Price Target

$56.69

(91.39% upside)

Analyst Consensus: Buy